What Is My Veterinary Practice Worth? How Buyers Value It
A plain-English valuation guide for owners of $1M–$50M veterinary practices — what a corporate consolidator actually pays versus what an online calculator shows, and the single lever that moves your multiple by 3–6 full turns.
Updated 2026-06-12·Updated 2026 · 12 min read·Healthcare Services & IT
Typical multiple
4.0x – 14.0x
Priced on Adjusted EBITDA · Typical 8.5x
Triangulated from Ackerman Group Q1/Q2 2025 reports, SovDoc 2025, Transitions Elite/PetVet pricing disclosures, Octus VSO 2025 coverage, and the SVP/MVP Dec 2024 platform print
- Adjusted EBITDA multiple
- 4.0x–14.0x
- Typical normalized EBITDA margin
- 15–20%
- LMM midpoint (multi-doctor GP)
- 8.5x
- Biggest multiple driver
- Doctor count
The short answer
A veterinary practice is worth a multiple of its associate-adjusted EBITDA, not its revenue — and doctor count explains most of the spread. In 2026, solo owner-dependent practices sell at 3.5x–6x to SBA-financed individual buyers, while multi-doctor GP practices with $500K+ EBITDA clear 8x–12x from PE-backed consolidators, and premium $1M+ EBITDA practices reach 12x–15x from named platforms such as Mission Pet Health, PetVet, and AmeriVet.[1][5][7]
Estimate vs. reality
A calculator estimate is not what a buyer pays
Type your revenue into a free calculator and it applies a flat percentage or a generic EBITDA multiple that ignores the single most important variable in veterinary M&A: how many DVMs produce your revenue. A corporate buyer pays for transferable associate-driven production, not for the owner's personal clinical output — and that gap routinely moves value 30–60% in either direction.[11][15]
- Revenue or reported earnings × a generic veterinary industry multiple
- No adjustment for owner-DVM production vs. associate production
- Stale or public-company multiples not adjusted for private illiquidity
- No view of doctor count, wellness plan penetration, or employment-agreement structure
- One point estimate with no buyer-pool segmentation (individual vs. PE vs. strategic)
- Associate-adjusted EBITDA validated in diligence — owner-DVM comp normalized to market replacement wage
- A multiple set by DVM count, EBITDA scale, specialty mix, and the competitive tension among named buyers
- Transferable production: associates carry 30–40%+ of revenue so cash flow survives the owner's exit
- Wellness plan penetration that partially hedges the three-year invoice-growth headwind
- A structured price — cash at close, mandatory rollover equity, earnout, and a 2–5 year employment agreement
In an owner-operated single-DVM practice, reported EBITDA is entirely dependent on the owner's personal production — the buyer normalizes that to a market replacement wage and the adjusted figure can run materially below reported earnings, collapsing the applicable multiple and the buyer pool simultaneously.[12][15]
Earnings basis
SDE or EBITDA? It depends on your size
The most consequential framing question in veterinary valuation is which earnings metric applies and who the buyer is — both answers flip with your doctor count and EBITDA scale, not just your revenue.
| Business size | Priced on | Typical multiple | What's going on |
|---|---|---|---|
| Under ~$2M value (solo / single DVM) | SDE / % revenue | 3.5x – 6.0x EBITDA or ~70–80% of revenue | Owner-dependent; SBA-financed individual buyers cap price at ~$5M deal size. PE platforms decline to bid. Transition contracts of 2–5 years are routinely required. |
| $2M – $10M EV (2-DVM, regional add-on) | Adjusted EBITDA | 6.0x – 8.0x | Multi-doctor lift is active; associate-adjusted EBITDA replaces SDE. Regional consolidators and the lower end of PetVet's band apply. Rollover equity begins to appear. |
| $10M – $50M EV (3–4+ DVMs, PE add-on sweet spot) | Adjusted EBITDA | 8.0x – 12.0x | Named platform buyers compete: Mission Pet Health, PetVet, AmeriVet, NVA. Wellness plan penetration and clean QoE rewarded. Some corporate deals cleared 12.5x at the top of this band in Q2 2025.[1] |
| $50M+ EV (multi-DVM GP + specialty or platform tier) | Adjusted EBITDA | 12.0x – 18.0x | Specialty/ER hospitals trade 12x+ as a baseline; GP platforms with $1M+ EBITDA reach 12–15x per Mahan Law; SVP/MVP platform recap closed December 2024 at ~17–18x.[6][7] |
Per the IBBA/M&A Source Market Pulse framing, businesses valued under ~$2M are priced on SDE (which adds back the owner's full compensation); $2M and above are priced on adjusted EBITDA (which subtracts a market-rate replacement manager). For veterinary practices, this pivot is overlaid with a corporate-buyer threshold: PE platforms require 2+ DVMs and typically $500K+ adjusted EBITDA before engaging — below that, the buyer is an SBA-financed individual and the pricing basis shifts toward SDE or a revenue percentage.[13]
Interactive estimate
Estimate what your veterinary practice is worth
Move the sliders. The range reflects how each driver pushes the multiple up or down for a veterinary practice. Treat it as a planning anchor — not a formal valuation.
The defining variable in veterinary M&A. A solo owner-DVM caps at 3.5–6x; two DVMs lifts to 6–8x; 3+ DVMs with associate-led production clears 8–12x add-on territory. Solo at the low end; multi-doctor platform-scale at the high end.
Corporate buyers underwrite associate-driven revenue that survives the owner's exit. Associates carrying 40%+ of production are the key transferability signal. Below 20%, expect a meaningful haircut from corporate buyers.
Wellness plans convert transactional invoicing into recurring revenue — important protection against the three-year industry invoice-growth headwind. 15%+ of revenue is the threshold corporate underwriters reward.[1]
Specialty referral and emergency hospitals trade at 12x+ as a baseline. Corporate ownership is ~75% in the specialty/ER tier, creating more bidders. Pure GP at the low end; meaningful specialty mix at the high end.[3]
Estimated enterprise value
$3.6M – $5.4M
Implied multiple: 6.0x – 9.0x Adjusted EBITDA
Illustrative planning range only, based on typical veterinary multiples and driver sensitivities — not a formal valuation or an offer.
Methodology
The three ways a veterinary practice gets valued
A credible valuation triangulates across all three. Any single number in isolation is suspect.
Market approach — comparable veterinary transactions
Primary method for healthy multi-doctor practicesThe market approach values your practice against actual sale prices and multiples of comparable veterinary businesses. It dominates because the named corporate-buyer pool is relatively small and the pricing grids are publicly disclosed: PetVet (KKR) publishes 7.5–9.5x for multi-doctor GPs and 10x+ for $2M+ EBITDA standouts; Mahan Law cites 12–15x for $1M+ EBITDA premium-tier practices; and the Mission Pet Health / SVP + MVP recap closed at ~17–18x in December 2024.[5][6][7] This creates a legible three-tier pricing ladder: individual SBA buyer, regional PE add-on, and named platform — and your doctor count plus EBITDA scale determines which tier you live in.
Advisors and buyers source private add-on comps from Ackerman Group's quarterly reports, DealStats, and PitchBook, then adjust for DVM count, specialty mix, wellness plan penetration, employment-agreement structure, and geographic buyer density.[1][4]
Income approach — DCF pricing the invoice-growth headwind
Cross-check; essential given negative macro trendThe income approach discounts forecast cash flows to present value, and in veterinary it carries more analytical weight than in most other sectors because of a specific macro variable: US veterinary invoice growth was negative in 2022, 2023, and 2024 — down more than 2% per year on average — and Ackerman Group calls this "the variable that will determine valuation trends for years."[1] Terminal-value assumptions must be defended explicitly, not assumed away.
In practice, a buyer models three scenarios: a base case of flat-to-slightly-negative invoice growth recovering to 1–2% by 2028, a bear case of continued negative growth, and a bull case where wellness plan penetration above 20% insulates the practice from invoice-level headwinds. The DCF terminal value is then anchored to a market exit multiple — typically the PetVet 7.5–9.5x band for a qualifying multi-doctor asset — rather than a perpetual-growth assumption.[2][5]
Asset approach — floor check and SBA lending constraint
Floor for solo / SBA-financed transactionsThe asset approach — summing equipment, leasehold improvements, inventory, working capital, and the goodwill value of the patient list — materially understates operating value for any healthy practice. For a multi-doctor practice with strong EBITDA it sets a floor, not a price. It becomes structurally relevant in one specific context: SBA-financed individual-buyer transactions, where the lender models loan-to-value against tangible assets and goodwill of the patient list, and the SBA 7(a) program caps total deal size at approximately $5M — a constraint that limits the applicable multiple more than the buyer's willingness to pay.[9]
If the asset-based value lands within ~30% of the market-comp value, the operating EBITDA quality should be re-tested — usually owner-DVM compensation is under-normalized or wellness plan revenue is being mis-counted in the revenue bridge.[2]
Value drivers
What moves the multiple for a veterinary practice
Multi-doctor scale — the defining lever
+3.0x – 6.0xA 3–4+ DVM practice reduces key-person risk and gives PE buyers a transferable clinical operation — one whose cash flow survives the owner's exit. Solo practices trade at 3.5–6x; multi-doctor practices clear 7–9x as regional add-ons; the jump is steepest at the 3-DVM threshold where the owner moves from sole provider to clinical director.[1][5] When associates carry 30–40%+ of clinical revenue, transferability is demonstrated and commands platform-tier pricing.
$1M+ EBITDA — the named-platform threshold
+3.0x – 6.0xPE's hard underwriting threshold. Mahan Law cites 12–15x for $1M+ EBITDA practices; PetVet (KKR) publicly pays 10x+ for $2M+ EBITDA standouts.[5][7] Below $500K EBITDA the buyer pool is mostly individuals and regional groups; at $1M+ four named consolidators compete — Mission Pet Health, PetVet, AmeriVet, and NVA — and that competitive tension is the structural reason for the multiple re-rating.[3][6] Sellers near this threshold should invest in associate hiring and wellness plan penetration as a deliberate pre-sale valuation strategy.
Specialty / emergency / exotic mix
+1.0x – 3.0xSpecialty referral and emergency hospitals operate in a fundamentally different market: higher revenue per visit, stickier referral relationships, and — critically — ~75% corporate ownership in the specialty/ER tier versus 25–50% of GP practices.[3] More corporate ownership means more bidders on every deal. SovDoc 2025 cites specialty/ER at 12x+ as a baseline; practices with meaningful specialty mix earn a blended multiple above the pure-GP band.[4]
Wellness plan recurring revenue base
+0.5x – 1.5xWellness plans convert transactional invoicing into recurring, predictable revenue. This matters especially now: with negative invoice growth three years running, recurring plan revenue partially insulates EBITDA from the macro headwind.[1] Penetration above 15% of revenue is the threshold corporate underwriters reward — track plan attach rate and annual churn, because buyers will build both into their DCF models.[2]
Solo owner-dependency — the DVM cap
−3.0x – −5.0x (floors at 3.5–6x)A single-DVM, owner-reliant practice has no transferable production engine. The buyer is effectively buying a job. Serenity Vet's published worked example values such a practice at ~3.5x EBITDA to an SBA-funded individual buyer — the corporate platform pool declines to bid entirely.[9] The structural cap: SBA financing tops out at ~$5M deal size, which means a solo practice earning $500K+ EBITDA is priced out of SBA routes yet too owner-dependent for corporate routes — the worst-valued quadrant in veterinary M&A.
Macro: negative invoice growth, three consecutive years
Sector-wide compression vs. 2021 peakUS veterinary invoice growth was negative in 2022, 2023, and 2024 — down more than 2% per year on average. Ackerman Group calls this "the variable that will determine valuation trends for years."[1] This is the single most important reason why 2021 platform multiples are not the comparable today. Recap multiples are unlikely to re-expand to 2021 highs until invoice growth turns consistently positive. Practices with wellness plan penetration above 15% and 3+ DVMs demonstrably decouple from the invoice-growth drag.[2][4]
Equine / large-animal mix
−1.0x – −2.0xEquine and large-animal practices face a materially narrower corporate buyer pool — most PE consolidators focus exclusively on small-animal companion practices. A practice deriving 30%+ of revenue from large-animal work will find that the Mission Pet Health / PetVet tier declines to bid, leaving individual veterinarians and regional farm-animal specialists as the primary exit path. That narrower pool compresses the achievable multiple toward the individual-buyer band.[4][9]
Thin EBITDA margin or deteriorating revenue trajectory
−1.0x – −2.5xEBITDA margins below 12–13% signal either underpriced services, an overpaid owner, or genuine operating inefficiency — each of which a buyer's QoE team will interrogate. Combined with the sector-wide invoice-growth headwind, declining year-over-year revenue forces a DCF bear-case scenario that can compress platform-tier bids by one to two full turns. Three years of flat or declining revenue at the point of sale is the fastest way to land in the individual-buyer pool regardless of doctor count.[1][4]
Worked example
A $4M-revenue multi-doctor GP practice, step by step
An illustrative multi-doctor general practice with three DVMs, wellness plan adoption above 15%, located in a suburban metro market, and two associate DVMs under multi-year employment agreements. Numbers are illustrative, not a specific company.
Annual revenue
$4.0M
Multi-doctor GP — companion animal only
Adjusted EBITDA
$720K
≈18% margin after normalizing owner-DVM comp to market replacement wage and removing personal add-backs[2][12]
Applied multiple
10.0x
3+ DVMs, wellness plan penetration, low owner dependence, PE add-on sweet spot[1][5]
Enterprise value
≈ $7.2M
Adjusted EBITDA × multiple
Indicative result
≈ $7.2M enterprise value
The solo-owner contrast illustrates the downside: the same $4M revenue as a single-DVM owner-dependent practice at a 12% margin is $480K EBITDA — and at 4.5x (the individual-buyer rate) that is ≈ $2.2M, roughly one-third of the multi-doctor outcome at identical revenue.[9][5] Doctor count and transferability, not revenue, are what determine value. This is illustrative, not an offer or a formal valuation.
Cost & who does it
What a veterinary practice valuation costs — and who should do it
Before you anchor on any number, get your associate-adjusted EBITDA right — normalizing owner-DVM compensation is the single largest variable in veterinary valuation and consistently the item most misrepresented in self-prepared estimates.
Broker / advisor opinion of value
Free – $5,000
Best for
Testing the market, setting a realistic listing range
Fast; not certified and not accepted by the IRS or courts. Vet-specialist advisors (e.g., Ackerman Group) often provide a preliminary normalized-EBITDA estimate as part of engagement discussions.
Formal certified appraisal (USPAP)
$5,000 – $30,000+
Best for
Estate or gift tax, ESOP, litigation, partner buyout, SBA loan underwriting
Performed by a credentialed appraiser (CVA / ABV / ASA); defensible to the IRS and courts. Required for any tax, legal, or ESOP trigger.
Quality of earnings (QoE)
$15,000 – $75,000+
Best for
Validating associate-adjusted EBITDA before going to market; pre-empting re-trades on owner-DVM add-backs
Not an audit; tests add-backs and working capital, and typically pays for itself in re-trade protection. The modern best practice for any practice owner above $500K EBITDA preparing for a corporate sale process.
For most veterinary practice owners preparing for a corporate sale, the right sequence is: an advisor opinion of value to orient the range and confirm which buyer tier you qualify for, a sell-side QoE to document and defend associate-adjusted EBITDA (the item corporate QoE teams scrutinize most), and a certified appraisal only if an estate, ESOP, or litigation trigger requires it. A standard advisor opinion typically runs free to ~$5,000; certified appraisals ~$5,000–$30,000+ depending on complexity.[13][14] With Ad Astra's verified $1B+ in closed transaction value, a confidential opinion of value is a no-obligation place to start — book a confidential call.
Before you sell
How to increase your valuation before going to market
The gap between a 3.5x solo-owner practice and a 10x+ multi-doctor asset is operational, not accidental — and most of the levers can be moved in a 12–24 month window. Our value enhancement work is built around the three that move the veterinary multiple most.
Add associate DVMs so associates generate 40%+ of production
+3.0x – 5.0xThis is the highest-ROI pre-sale investment in veterinary M&A. Hiring one associate DVM can trigger a 3–4x multiple re-rating on the same underlying EBITDA by shifting the practice from the SBA-financed individual-buyer tier into the PE-platform tier.[5][9] The mechanism: corporate buyers underwrite transferable production — revenue that survives the owner's exit. Document the associate's production share separately in your practice management system at least 12 months before initiating a process.
Build wellness plan penetration above 15% of revenue
+0.5x – 1.5xWith three consecutive years of negative invoice growth across the US veterinary sector, recurring wellness plan revenue is the most visible internal hedge against the macro headwind — and the threshold that PE underwriters explicitly reward.[1][2] Begin tracking plan attach rate (% of active clients enrolled) and annual churn 18 months before sale so you can present clean trend data. Aim for at least 15% of revenue from wellness plan billings.
Normalize financials and document EBITDA add-backs before process
+1.0x – 2.0x on applied multiple; protects re-trade riskOwner-DVM compensation normalization, family payroll adjustments, owner vehicle expenses, and deferred equipment capex are the four items corporate QoE teams examine first — and undocumented add-backs are the most common source of re-trades and price reductions in veterinary deals.[12][15] Commission a sell-side QoE 6–12 months before going to market: it validates your adjusted EBITDA, preempts buyer pushback, and positions you to run a competitive multi-party process on a clean number. Clean, documented financials also allow you to present all four named buyers (Mission Pet Health, PetVet, AmeriVet, NVA) with identical information — the competitive tension that drives bids toward the top of the band.[3][5]
FAQ
Common questions about veterinary practice valuation
Go deeper on veterinary practice multiples
Value another business
From estimate to real number
Get an owner-grade valuation of your veterinary practice
A confidential 30-minute call with Clayton or Joe gives you a real range, the adjustments we'd apply to your reported earnings, and the one or two moves that close the gap fastest — built on healthcare services & it deal data.
- [1] Ackerman Group — Q1 2025 Veterinary Industry Market Update
- [2] Ackerman Group — EBITDA in Vet Valuations
- [3] Octus — Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure (2025)
- [4] SovDoc — How to Value a Veterinary Practice (2025)
- [5] Transitions Elite — PetVet Purchase Price (2025)
- [6] Transitions Elite — Southern Veterinary Partners Acquisition
- [7] Mahan Law — Buying a Veterinary Practice: Practice Valuation — What Should I Pay?
- [8] Yahoo Finance — Candy maker Mars is biggest vet (Mars / VCA analysis)
- [9] Serenity Vet — How to Value a Veterinary Practice: Complete 2026 Guide
- [10] First Page Sage — Veterinary Practice EBITDA Valuation Multiples
- [11] Wipfli — Are business valuation online calculators accurate?
- [12] MidStreet — Adjusted EBITDA: Add-backs and Common Errors
- [13] Baton — How Much Does a Business Appraisal Cost?
- [14] CT Acquisitions — Quality of Earnings (QoE) Report: 2026 Guide
- [15] CT Acquisitions — Business Valuation Calculator: Estimate Your Business Worth
Ranges represent typical lower middle market transactions; individual deals may fall outside the band based on buyer thesis, deal structure, and company-specific factors. This page is informational and not a formal valuation opinion.